PCN18 OUTCOMES RESEARCH OF BORTEZOMIB INDICATED FOR MULTIPLE MYELOMA IN THE CONTEXT OF THE DUTCH REIMBURSEMENT POLICY FOR EXPENSIVE MEDICINES- THREATS TO THE INTERNAL VALIDITY OF THE INCREMENTAL EFFECTIVENESS ESTIMATE

Oct 1, 2009, 00:00
10.1016/S1098-3015(10)74270-4
https://www.valueinhealthjournal.com/article/S1098-3015(10)74270-4/fulltext
Title : PCN18 OUTCOMES RESEARCH OF BORTEZOMIB INDICATED FOR MULTIPLE MYELOMA IN THE CONTEXT OF THE DUTCH REIMBURSEMENT POLICY FOR EXPENSIVE MEDICINES- THREATS TO THE INTERNAL VALIDITY OF THE INCREMENTAL EFFECTIVENESS ESTIMATE
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)74270-4&doi=10.1016/S1098-3015(10)74270-4
First page :
Section Title :
Open access? : No
Section Order : 196
Categories :
Tags :
Regions :
ViH Article Tags :